Spiro[1,4-dihydro-1,8-naphthyridine-3,1'-cyclopropane]-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Spiro[1,4-dihydro-1,8-naphthyridine-3,1'-cyclopropane]-2-one
• 英文别名: spiro[1,4-dihydro-1,8-naphthyridine-3,1'-cyclopropane]-2-one
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.2
• InChiKey: XKDVIDRLDMPOKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] ALKYLIDINE SUBSTITUTED HETEROCYCLYL DERIVATIVES AS ANTI-BACTERIAL AGENTS<br/>[FR] DÉRIVÉS D'HÉTÉROCYCLYL SUBSTITUÉS PAR ALKYLIDINE COMME AGENTS ANTIBACTÉRIENS
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2015071780A1

  公开（公告）日：2015-05-21

  The present invention relates to alkylidine substituted heterocyclyl derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors; I in which P, Q, Ri, R2, R3 and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FABI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明涉及公式（1）的烷基亚甲基取代的杂环衍生物，其可能作为抗菌剂在治疗上有用，更具体地是FabI抑制剂;其中P，Q，Ri，R2，R3和“n”具有规范中给出的相同含义，并且其药学上可接受的盐或药学上可接受的立体异构体在疾病或紊乱的治疗和预防中有用，特别是在抑制乙酰辅酶A还原酶酶（FABI）活性方面具有优势的疾病或紊乱的使用。本发明还提供合成和给予FabI抑制剂化合物的方法。本发明还提供包含至少一种FabI抑制剂化合物的药物制剂，以及其药学上可接受的载体，稀释剂或赋形剂。
• [EN] FUSED PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS PYRIDINE FONDUS, EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014072930A2

  公开（公告）日：2014-05-15

  The present invention relates to fused pyridine derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors, in which P, Q, R1, R2, R3 and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FABI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.